title: Aprotinin-associated risks in off-pump coronary artery bypass grafting.
abstract: BACKGROUND
  Little data is available regarding the safety of using the serine protease inhibitor aprotinin in off-pump cardiac surgery. We retrospectively assessed the risks of administering the drug to adult patients undergoing off-pump coronary artery bypass grafting (OPCABG).
  
  
  METHODS
  Aprotinin was administered as a bolus of 1 or 2 million kallikrein inhibiting units to 391 patients following median sternotomy; 370 control patients underwent surgery during the same time period without receiving aprotinin. No other antifibrinolytic agents were administered.
  
  
  RESULTS
  Preoperative characteristics, length of ICU and hospital stay were similar between the mostly medium-risk aprotinin and the control patients. Postoperative cardiac, renal, neurological, and respiratory complications and hospital mortality occurred with comparable frequencies in both groups. Levels of myocardial enzymes during the first 72 h after surgery also did not differ significantly.
  
  
  CONCLUSIONS
  Use of aprotinin in OPCABG was not associated with a higher incidence of hospital mortality, cardiovascular, renal, or other complications. Given the good safety profile in this large patient population we suggest that aprotinin could still be a valid antifibrinolytic treatment option in OPCABG.
authors.affiliation: Cardiovascular and Thoracic Surgery, Heart Center Leipzig, Leipzig, Germany. heartbeatgermany@aol.com
authors.forename: H B
authors.initials: HB
authors.lastname: Bittner
authors.forename: M
authors.initials: M
authors.lastname: Lange
authors.forename: J
authors.initials: J
authors.lastname: Lemke
authors.forename: A
authors.initials: A
authors.lastname: Rastan
authors.forename: F W
authors.initials: FW
authors.lastname: Mohr
mesh_terms: D000368:Aged; D007611:Aprotinin / Q000008:administration & dosage / Q000009:adverse effects*; D047549:Coronary Artery Bypass, Off-Pump / Q000009:adverse effects*; D003402:Creatine Kinase / Q000032:analysis; D005260:Female; D006490:Hemostatics / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D012189:Retrospective Studies; D018570:Risk Assessment; D056346:Sternotomy / Q000379:methods; D016896:Treatment Outcome
chemical_list: D006490:Hemostatics; D007611:Aprotinin; D003402:Creatine Kinase